Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Braftovi plus Mektovi a New Combination for Metastatic Melanoma with BRAF Mutation

October 2018 Vol 4 No 5

In June 2018, the FDA approved 2 new drugs Braftovi and Mektovi (encorafenib and binimetinib; from Array BioPharma) to be used in combination for the treatment of patients with unresectable (can’t be removed by surgery) or metastatic (spreading) melanoma and a BRAF V600E or V600K mutation. At the same time, the FDA also approved the THxID-BRAF kit, which is a test to identify a BRAF mutation. Patients should have this new genetic test to identify the BRAF mutation before using this new targeted drugs combination.

The FDA approved this new combination based on a clinical trial of 577 patients with unresectable or metastatic melanoma and BRAF V600E or BRAF V600K mutation. The results showed that the average time without disease progression was 14.9 months with the new combination compared with only 7.3 months with another drug, Zelboraf (vemurafenib), which was previously approved for patients with melanoma.

The most common side effects with the new combination were fatigue, nausea, diarrhea, vomiting, abdominal pain, and joint inflammation. A few patients (5%) discontinued treatment with the new drugs because of bleeding and headache.

Recommended For You